Home
About
Company Profile
Culture
History
Honors
Products
Formulation Products
API & Intermediate
R&D
R&D Platform
Research Strength
Social Responsibility
Sustainable Development
Public Welfare Activity
News
Company News
Media Coverage
Notice
Contact
Cooperation Inquiry
Employee Style
Adverse Drug Reaction Reporting
Investor Relations
Announcement & Notice
Performance Report
Investor Communication
English
中文简体
Media reports
Notices and Announcements
Hunan Xianshi Pharmaceutical Receives NMPA Marketing Approval for Two Strengths of Dapoxetine Hydrochloride Tablets
CHANGSHA, Jan 09, 2026 — Hunan Xianshi Pharmaceutical Co., Ltd. has obtained marketing authorization from the National Medical Products Administration (NMPA) for Dapoxetine Hydrochloride Tablets in two specifications: 30 mg and 60 mg.
→
View Details
01-09
2026
Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing
NANJING, Nov 26, 2025 — The 91st National Pharmaceutical Fair (PHARMCHINA) was held at Nanjing International Expo Center from November 19 to 21. The exhibition gathered over 2,000 top pharmaceutical enterprises and more than 100,000 industry practitioners, acting as a key platform for displaying industrial trends, showcasing corporate strengths and developing commercial cooperation.
11-26
2025
Hunan Xianshi Pharmaceutical cordially invites you to visit Booth 8E28-2 in Hall 8 at the 91st National Pharmaceutical Fair!
CHANGSHA, Nov 7, 2025 — Hunan Xianshi Pharmaceutical Co., Ltd. will participate in the 91st National Pharmaceutical Fair from November 19 to 21. Its exhibition booth is located at Booth 8E28-2, Hall 8, where the company will display a complete lineup of core commercial products and pipeline candidates.
11-07
Focusing on Advances in Orthopedics: Xianshi Pharmaceutical Presents Core Products at Yunnan Provincial Orthopedic Academic Conference
KUNMING, Nov 06, 2025 — The 11th Yunnan Medical Association Orthopedics Academic Conference (3rd Session) recently concluded at Kunming Yun’an Convention Center. Organized by the Orthopedics Branch of Yunnan Medical Association and co-hosted by top local hospitals, the event gathered leading orthopedic experts and frontline clinicians to share cutting-edge surgical technologies, innovative diagnosis and treatment plans, and the latest industry development trends.
11-06
Three Products of Hunan Xianshi Pharmaceutical Selected in China’s 11th National Volume-Based Drug Procurement
CHANGSHA, Oct 28, 2025 — The preliminary winning list of the 11th round of China’s National Volume-Based Drug Procurement was released on October 27. Three core pharmaceutical products developed by Hunan Xianshi Pharmaceutical Co., Ltd., namely Procaterol Hydrochloride Inhalation Solution, Avatrombopag Maleate Tablets and Roxadustat Capsules, have been shortlisted in the program. The achievement recognizes the company’s product quality and R&D strength, and marks key progress in improving affordable medicine accessibility for domestic patients.
10-28